Senate Infrastructure Legislation ‘Pay Fors’ Not So Bad For Pharma But Real Threat is Ahead
Senate negotiators opt to delay but not withdraw the pharma-backed rebate rule and target a relatively small reform aimed at allowing Medicare Part B to recoup the cost of leftover physician-administered drugs
You may also be interested in...
A policy eliminating rebates in the Medicare Part D program will be delayed until Jan. 1, 2026 – and is very likely to be repealed altogether. If that staves off more draconian reforms, the biopharma industry will celebrate.
Manufacturers who sell single-use vials for products covered by Part B have about 16 months to consider pricing or packaging changes that may minimize exposure to a new refund for ‘wasted’ drug.
Senate Finance Committee directed to provide ‘nearly all’ of the spending offsets for the $3.5tn package; Committee chair Ron Wyden is focused on authorizing the US government to directly negotiate drug prices in Medicare.